journal cover

How I treat primary CNS lymphoma

Blood

May 27, 2011

A J M Ferreri

Abstract

Primary CNS lymphoma (PCNSL) is a rare malignancy with peculiar clinical and biologic features, aggressive course, and unsatisfactory outcome. It represents a challenge for multidisciplinary clinicians and scientists as therapeutic progress is inhibited by several issues. Molecular and ...read more

Mentioned in this Paper

Tumor Cells, Uncertain Whether Benign or Malignant
Stem Cell Transplant
Myopathy
Ribodoxo
Antineoplastic Chemotherapy Protocols
Primary Malignant Neoplasm
Vdcp Protocol
Central Nervous System Neoplasms, Primary
Poor Performance Status
Rectodelt
5
225
Paper Details
References
  • References82
  • Citations65
12345...
  • References82
  • Citations65
12345...

Similar Papers Found In These Feeds

Neurotoxicity, Inflammation & Neuroprotection

The end result of the inflammatory process, neurotoxicity and/or neuroprotection, is a function of the fine balance between the two cellular systems, i.e., of the complex signaling relationships between anti-inflammatory neuroprotective factors (neurotrophins and other chemical mediators) and proinflammatory neurotoxic factors (tnf, free radicals, certain cytokines, etc). Here are the latest discoveries pertaining to neurotoxicity, inflammation and neuroprotection.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Related Papers

Best Practice & Research. Clinical Haematology

Primary CNS lymphoma

Best Practice & Research. Clinical HaematologyMarch 14, 2012
A J M Ferreri, Emerenziana Marturano
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology

Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10

Journal of Clinical Oncology : Official Journal of the American Society of Clinical OncologyDecember 19, 2002
Lisa DeAngelisRadiation Therapy Oncology Group Study 93-10
© 2020 Meta ULC. All rights reserved

How I treat primary CNS lymphoma

Blood

May 27, 2011

A J M Ferreri

PMID: 21613254

DOI: 10.1182/blood-2011-03-321349

Abstract

Primary CNS lymphoma (PCNSL) is a rare malignancy with peculiar clinical and biologic features, aggressive course, and unsatisfactory outcome. It represents a challenge for multidisciplinary clinicians and scientists as therapeutic progress is inhibited by several issues. Molecular and ...read more

Mentioned in this Paper

Tumor Cells, Uncertain Whether Benign or Malignant
Stem Cell Transplant
Myopathy
Ribodoxo
Antineoplastic Chemotherapy Protocols
Primary Malignant Neoplasm
Vdcp Protocol
Central Nervous System Neoplasms, Primary
Poor Performance Status
Rectodelt
5
225

Similar Papers Found In These Feeds

Neurotoxicity, Inflammation & Neuroprotection

The end result of the inflammatory process, neurotoxicity and/or neuroprotection, is a function of the fine balance between the two cellular systems, i.e., of the complex signaling relationships between anti-inflammatory neuroprotective factors (neurotrophins and other chemical mediators) and proinflammatory neurotoxic factors (tnf, free radicals, certain cytokines, etc). Here are the latest discoveries pertaining to neurotoxicity, inflammation and neuroprotection.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Related Papers

Best Practice & Research. Clinical Haematology

Primary CNS lymphoma

Best Practice & Research. Clinical HaematologyMarch 14, 2012
A J M Ferreri, Emerenziana Marturano
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology

Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10

Journal of Clinical Oncology : Official Journal of the American Society of Clinical OncologyDecember 19, 2002
Lisa DeAngelisRadiation Therapy Oncology Group Study 93-10
Paper Details
References
  • References82
  • Citations65
12345...
  • References82
  • Citations65
12345...
/papers/how-i-treat-primary-cns-lymphoma/21613254